Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study
Wirksamkeit und Sicherheit von Hetrombopag bei chemotherapiebedingter Thrombozytopenie bei soliden Tumoren: retrospektive Studie
Frontiers in Oncology · 28.10.2025 · 15
DOI: 10.3389/fonc.2025.1670029 ↗Auf einen Blick
Bei 187 Patient:innen mit CIT war die Kombination aus Hetrombopag und rhTPO wirksamer als die Monotherapien. Hetrombopag allein zeigte eine vergleichbare Wirkung zu rhTPO und rhIL-11.
Fragestellung
Wie wirksam und sicher ist Hetrombopag bei chemotherapieinduzierter Thrombozytopenie (CIT) bei Patient:innen mit soliden Tumoren?
Methode
Retrospektive Kohortenstudie bei Patient:innen mit CIT nach Chemotherapie bei soliden Tumoren; Einteilung in vier Behandlungsgruppen von Januar 2023 bis Dezember 2024.
Ergebnisse
187 Patient:innen: 64 rhTPO, 37 Hetrombopag, 36 Kombination, 50 rhIL-11. Die Kombination zeigte höhere Ansprechrate, bessere PLT-Werte an Tag 7 und 14 und die kürzeste Zeit bis PLT ≥100×10^9/L (P<0,05).
Schlussfolgerung der Autor:innen
Die Kombination aus Hetrombopag und rhTPO war den Monotherapien überlegen; Hetrombopag allein war ähnlich wirksam wie rhTPO und rhIL-11.
Kernaussagen
- Kombination aus Hetrombopag und rhTPO mit höherer Ansprechrate
- Schnellere PLT-Erholung und kürzere Recovery-Zeit
- Ähnliche Transfusions- und AE-Raten in allen Gruppen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.10.2025. Verfasst von Yuan Yuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
This study aims to evaluate the efficacy and safety of hetrombopag in the management of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors, utilizing a retrospective cohort study design.
Methods
The study population comprised patients experiencing CIT due to chemotherapy for solid tumors, who received treatment at the General Hospital of Northern Theater Command from January 2023 to December 2024. Participants were categorized into four distinct cohorts based on their treatment regimens: the recombinant human thrombopoietin (rhTPO) monotherapy group, the hetrombopag monotherapy group, the combination therapy group (hetrombopag with rhTPO), and the recombinant human interleukin-11 (rhIL-11) monotherapy group. The primary outcomes evaluated included treatment response rate, alterations in platelet count (PLT), time to PLT recovery, differences in PLT counts pre- and post-treatment; secondary outcome measured encompassed rates of platelet transfusion, and incidence of adverse events (AEs).
Results
The study included a total of 187 patients, distributed as follows: 64 in the rhTPO group, 37 in the hetrombopag group, 36 in the combination therapy group, and 50 in the rhIL-11 group. The hetrombopag + rhTPO group exhibited a significantly higher treatment response rate (P<0.05) compared to the other three groups. Furthermore, this group showed superior PLT levels on days 7 and 14, a greater increment in PLT post-treatment, and the shortest median time to PLT recovery to ≥100×10 9 /L (P<0.05). Hetrombopag monotherapy demonstrated non-inferior PLT dynamics and treatment response rates compared to rhTPO/rhIL-11 (P>0.05). The four groups exhibited comparable PLT transfusion rates and a AEs incidence (P>0.05).
Conclusion
The combination of hetrombopag and rhTPO therapy exhibits superior efficacy compared to monotherapy in the treatment of CIT in patients with solid tumors. This combination therapy is associated with rapid elevation of platelet counts and a shortened recovery period, while maintaining a favorable safety profile. Furthermore, hetrombopag monotherapy has shown efficacy comparable to that of rhTPO and recombinant human interleukin-11 (rhIL-11), thereby supporting its recommendation for clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang, China.
Zitieren
APA
Yuan, Y., Tong, Q., Liu, J. H., & Kang, Y. (2025). Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1670029
Vancouver
Yuan Y, Tong Q, Liu JH, Kang Y. Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1670029
BibTeX
@article{Yuan2025,
author = {Yuan, Yuan and Tong, Qiang and Liu, Jia-Hui and Kang, Ye},
title = {Efficacy and safety of hetrombopag in the treatment of chemotherapy-related thrombocytopenia in solid tumors: a retrospective study},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1670029}
}
EUVIMED